# FDA 483 - Matthew Brimberry, MD - January 30, 2026

Source: https://www.keypedia.com/records/483/matthew-brimberry-md/5a0bf365-a9f2-4237-99f3-1b7eed54d1db

> FDA 483 for Matthew Brimberry, MD on January 30, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Matthew Brimberry, MD
- Inspection Date: 2026-01-30
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - West III
- Summary: An FDA inspection of Matthew Brimberry, MD, a clinical investigator in Austin, TX, revealed a significant issue with the conduct of an investigation. Specifically, a medication error was not reported to the sponsor within the required timeframe, and a subject was randomized into a study without documented confirmation of eligibility criteria, both deviations from the study protocol.

## Related Officers

- [Audrey J. Yarbrough](https://www.keypedia.com/people/audrey-j-yarbrough/1bab3d1a-3246-451e-96fb-4ce52185e850)

Company: https://www.keypedia.com/companies/matthew-brimberry-md/9dadce12-ded2-45b1-a4d9-ed78ddc905fc

Office: https://www.keypedia.com/offices/division-of-human-and-animal-food-operations-west-iii/2cda09a5-06c4-433f-9df0-0d7903a6efab